Compare Apple Inc (AAPL) vs AbbVie Inc (ABBV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs AbbVie Inc — how do they compare? Apple Inc trades at $304.86 (market cap $4.50T), while AbbVie Inc trades at $250 (market cap $438.19B). The key difference: Apple Inc is far larger — about 10.3× AbbVie Inc's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| AAPL | ABBV | |
|---|---|---|
Market Cap | $4.50T | $438.19B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $263.58 |
52-Week Low | $224.90 | $197.38 |
Enterprise Value | $4.52T | $502.45B |
Dividend Yield | 0.35% | 2.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal but strong fundamentals including a 26.91% net margin and three consecutive quarterly EPS beats. Recent news highlights AI potential via 2.5 billion devices and a Gemini partnership, though store closures and union disputes present headwinds.
The outlook balances robust earnings growth and cash flow against high valuation multiples and technical weakness. Upside to the $337.63 consensus target exists if AI initiatives accelerate, but competition and macroeconomic pressures remain key risks for investors.
AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.
Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →
